Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Gut. 2016 Jan 4;66(4):724–735. doi: 10.1136/gutjnl-2015-310033

Figure 4. The first-phase virological response correlates with the increase in STAT1 and TRAIL levels in NK cells during QUAD therapy.

Figure 4.

(A, B) Linear regression analysis of the decrease in viremia during the first 6h of QUAD therapy and the 24h-increase in STAT1 (A) and TRAIL (B) mean fluorescence intensity (MFI) on NK cells.

(C, D) Linear regression analysis of the decrease in viremia during the first 24h of QUAD therapy and the increase in STAT1 (C) and TRAIL (D) MFI on NK cells during the same period. R2: Coefficient of determination. Filled squares represent data from patients who developed a virological breakthrough at week 8 (n=1) or relapsed after the end of therapy (n=1).